The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | MRD-based response-adapted consolidation in NDMM post-transplant
Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, explains the first report of a monoclonal antibody-based quadruplet regimen with MRD-based response-adapted therapy in newly diagnosed multiple myeloma. Daratumumab, carfilzomib, lenalidomide and dexamethasone (Dara-KRd) indcution, followed by autologous transplant and MRD-guided Dara-KRd consolidation was given with promising results. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
